THE 2-MINUTE RULE FOR ABBV-744 IN THE TREATMENT OF DRUG-RESISTANT CANCERS

In Segment A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to establish Risk-free dosing regimen. Extra contributors are going to be enrolled for the recognized monotherapy dosign program. In Section B, members will receive oral ruxolitinib and ABBV-744 will be specified as "incorporate-on" therapy. In Segment C, mem